GuidelineSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025
[Clinical Practice and Quality Control Guidelines for Totally Implantable Venous Access Ports in Cancer Patients (2024)].
Guideline in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-Treatment Trajectories of Retained Totally Implantable Venous Access Ports After Anticancer Therapy: A Conditional Landmark Cohort Study.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Totally implantable venous access ports (TIVAP) are widely applied in cancer patients, primarily those requiring long-term intravenous infusion. Given the absence of clinical practice guidelines designed specifically for the use of TIVAP in cancer patients, the National Cancer Center, the Professional Committee of Interventional Oncology of Chinese Anti-Cancer Association, the Professional Committee on Minimally Invasive Intervention of World Association of Chinese Oncology, the Professional Committee of Intervention of Beijing Association of Oncology, and cancer prevention and control institutions from various provinces and cities have jointly established a guideline compilation committee comprising multidisciplinary experts. Drawing upon the latest research findings, this guideline has been formulated. It comprehensively covers the clinical application indications, preoperative preparation, intraoperative procedures, postoperative care, usage and maintenance, removal techniques, complication management, and quality control indicators related to TIVAP use in cancer patients. The recommendations were graded using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to ensure that the TIVAP technology can be used to serve cancer patients with greater safety and efficiency in clinical practice, thereby enhancing overall medical quality and patient satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.